In the recent double-blind clinical trial of Ld-IL2 therapy in SLE patients, we recorded a trend of a lower incidence of infection in the IL-2 group (6.9%, 2/29) compared with the placebo group (20.0%, 6/30) but the result did not reach a statistical significance [47]. The gene discussed is IL2; the disease is systemic lupus erythematosus.